Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
about
RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infectionGoing beyond the Control of Quorum-Sensing to Combat Biofilm InfectionsThe Three Bacterial Lines of Defense against Antimicrobial AgentsRole of quorum sensing in bacterial infectionsAnalysis of bacterial biofilms using NMR-based metabolomicsBiologically inspired strategies for combating bacterial biofilmsSmall molecule control of bacterial biofilmsEfficacy of the Quorum Sensing Inhibitor FS10 Alone and in Combination with Tigecycline in an Animal Model of Staphylococcal Infected WounddPABBs: A Novel in silico Approach for Predicting and Designing Anti-biofilm PeptidesMedicinal chemistry as a conduit for the modulation of quorum sensing.Factors contributing to the biofilm-deficient phenotype of Staphylococcus aureus sarA mutants.Superoxide dismutase is upregulated in Staphylococcus aureus following protoporphyrin-mediated photodynamic inactivation and does not directly influence the response to photodynamic treatment.Probing bacterial pathogenesis with genetics, genomics, and chemical biology: past, present, and future approaches.Quenching the quorum sensing system: potential antibacterial drug targets.Control of Biofilms with the Fatty Acid Signaling Molecule cis-2-Decenoic Acid.Impact of agr dysfunction on virulence profiles and infections associated with a novel methicillin-resistant Staphylococcus aureus (MRSA) variant of the lineage ST1-SCCmec IV.Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infectionsInactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureusMutation of traP in Staphylococcus aureus has no impact on expression of agr or biofilm formationPopulation-level virulence factors amongst pathogenic bacteria: relation to infection outcome.The efficacy of the quorum sensing inhibitor FS8 and tigecycline in preventing prosthesis biofilm in an animal model of staphylococcal infectionStaphylococcal biofilmsAttenuation of Edwardsiella tarda virulence by small peptides that interfere with LuxS/autoinducer type 2 quorum sensing.Discovery of Novel Bacterial Cell-Penetrating Phylloseptins in Defensive Skin Secretions of the South American Hylid Frogs, Phyllomedusa duellmani and Phyllomedusa coelestis.Prevention and treatment of Staphylococcus aureus biofilms.Quorum sensing inhibitors: a patent overview.Control of Biofilm Formation: Antibiotics and Beyond.Novel agents to inhibit microbial virulence and pathogenicity.Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner.Key genetic elements and regulation systems in methicillin-resistant Staphylococcus aureus.An insight into pleiotropic regulators Agr and Sar: molecular probes paving the new way for antivirulent therapy.Posttranscriptional regulation of oral bacterial adaptive responses.Subterfuge and sabotage: evasion of host innate defenses by invasive gram-positive bacterial pathogens.Strategies for combating bacterial biofilm infections.Investigational therapies targeting quorum-sensing for the treatment of Staphylococcus aureus infections.Drug treatments for prosthetic joint infections in the era of multidrug resistance.Quorum Quenching Strategy Targeting Gram-Positive Pathogenic Bacteria.Ambuic acid inhibits the biosynthesis of cyclic peptide quormones in gram-positive bacteria.Orthosiphon stamineus protects Caenorhabditis elegans against Staphylococcus aureus infection through immunomodulationIncreasing the presence of biofilm and healing delay in a porcine model of MRSA-infected wounds.
P2860
Q24682401-10AB1890-2127-44A3-B29C-C711101A60F7Q26749538-610ACAFB-0D9F-4E44-BB73-274B602CE2F8Q26786956-A6CCA951-B6BF-4BC1-83A5-3A91775007D5Q26798427-1FE3EB2D-E569-4A5F-B8EF-0009C0F68A94Q26851303-40F53D24-0067-49DF-9371-DB708C6BE0B3Q27006003-17264DFC-11D4-4408-BDE6-675C0635EA88Q28269575-98A958D2-47DE-430A-8753-CCC1872C6767Q28552608-8DF662E1-4C81-443B-93BB-B5C6D91A91ADQ28603750-66C25884-FD3D-4DCF-8280-FFF60914516FQ30429785-286BAB14-258E-42B2-AA85-9436DF3DFA0EQ33375040-EEB20160-BB64-4BE1-A073-CE2932191613Q33774632-FB36B72C-BFD6-4059-A993-BF13F91993DFQ33798373-BB483121-E5DB-44C8-93A4-ABADBA528947Q33805168-D6EE3E59-183A-46BE-A3A8-696CB0706B7CQ34503204-7648142B-BB3D-4A9C-8EA5-D7B6859E1F75Q34691308-88FB3A7E-E203-45FB-9CA8-57EB07C4A4B7Q35714452-5820BA3B-3774-43B2-A91F-212A57A353E6Q35947338-13EA987A-54C7-4117-BCFB-BE88E3FA1606Q35947369-1953206D-8D4B-4AE1-8FB6-A1DBAE0287C9Q37071140-D96B612A-A0B6-46B5-929E-9B9195A9AD7FQ37139168-209AA225-A5CC-444E-8B88-FB1322F90874Q37153224-B1D95A53-5CB1-44B9-9E82-35C97D757FF6Q37232414-D3D33CFC-EACD-4894-B5AD-7D9040B614F2Q37285649-3D6CCF97-FAD0-436F-8BC7-7E9F2489DDFEQ37482155-562BF16D-2CE3-4BB5-AE3D-088FBAAECB59Q37592265-80B03B17-120F-444D-8315-7EB2FB1E2577Q37593127-A370FC51-558C-4738-B8AB-3EB624832F96Q37780752-3B93EB8D-1DF3-4C17-8A88-384EBC1B1C04Q37860818-E333AC86-D807-4AB7-915E-E643308C7CEDQ38052949-0AE38739-AD35-4C73-A073-B8A41A4BB735Q38141165-58E48E3F-1F6B-42B0-8B31-BBA85EE2E7C0Q38201636-7E20A7A8-465D-465F-A946-736FF3C3287FQ38227102-5D4877CB-77D6-43E1-8159-186342565ADFQ38287542-3BB17B1B-DECB-40C1-81CE-E48A66F386B5Q38364049-E3AE68FA-F68B-4186-80D5-58215A478A13Q38800556-8BB6CB0C-1C3E-4DD4-B8B8-5B371A98B7A8Q38831839-0B5533B1-B4F3-4483-98A3-D0D06782E61EQ42111795-13AF58A2-65BD-438E-AFA9-AFD3859030FEQ42175755-554A36D2-9CE6-420F-82CC-4DBADB8416B7Q42652073-3246827A-D7D4-4E93-BCBD-EE57B6139EF7
P2860
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@en
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@nl
type
label
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@en
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@nl
prefLabel
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@en
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.
@nl
P2093
P2860
P356
P1476
Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP
@en
P2093
Andrea Giacometti
Carmela Silvestri
Giorgio Scalise
Joel B Braunstein
Naomi Balaban
Oscar Cirioni
Roberto Ghiselli
Vittorio Saba
P2860
P304
P356
10.1128/AAC.01097-06
P407
P577
2007-03-19T00:00:00Z